| | |

Is There a Risk for Depression Among Pleural Mesothelioma Patients?

risk for depression

Newly diagnosed pleural mesothelioma patients may be at higher risk for depression and that could be impacting their outcomes. 

 A new report finds that people diagnosed with advanced lung cancers are more likely to suffer from depression. Pleural mesothelioma is a form of lung cancer. 

This risk for depression appears to have an impact on patients’ quality of life, their pain, and even the number of complications they experience. 

Assessing the Risk for Depression in Cancer Patients

Researchers at Ohio State University directed the study. It included 186 patients with Stage IV non-small-cell lung cancer. The patients had not yet started their cancer treatment. 

Although pleural mesothelioma is not the same as non-small cell lung cancer, the two diseases share many of the same characteristics and are often treated similarly. Mesothelioma is an extremely rare form of lung cancer that is difficult to treat.

The researchers conducted telephone surveys to assess the risk for depression, physical symptoms, and functioning among the lung cancer patients. Based on the responses, they divided the patients into three categories. 

The good news is that 64 percent of the patients were either not depressed or only mildly so. But the bad news is that more than a third of the lung cancer patients were more seriously depressed. 

Fifty-two patients (28 percent) were moderately depressed and the remaining 15 (8 percent) had symptoms of severe depression. For the 36 percent of patients with moderate to severe depression, treatment – and daily life – appeared to be much harder.

Impacts of Depression in Mesothelioma

The findings suggest that the risk for depression could have far-reaching implications for pleural mesothelioma patients
The lung cancer patients with moderate to severe depression experienced a host of problems that impacted their lives. 

“Depression is just part of what these patients are dealing with,” says Barbara Andersen, PhD, Clinical Professor of Psychology at Ohio State. “It comes with this whole package of worse functioning, more physical symptoms, stress, anxiety and more. All of these can have negative effects on treatment, overall health, quality of life and disease progression.” 

Severely depressed patients had more pain and other physical symptoms. They also had trouble with day-to-day functioning. The moderately depressed patients also had symptoms but they were not as severe. 

“Some oncologists may have a mindset that ‘of course, you’re depressed, you have lung cancer.’ This may show an under-appreciation of the breadth of depressive symptoms and other difficulties which accompany it,” Andersen said.

Although no one has yet assessed the link between risk for depression and lung cancer treatment outcomes, Dr. Anderson says she expects there is an impact. 

The results of this study suggest that depression screening for newly diagnosed pleural mesothelioma patients might be a good idea. If screening identifies patients at high risk for depression, the right interventions might reduce their pain and help maintain their quality of life. 

Sources:

Andersen, BL, et al, “Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms”,  December 4, 2019, https://www.lungcancerjournal.info/article/S0169-5002(19)30729-9/fulltext

Grabmeier, Jeff, “Depression affects one-third of lung cancer patients”, December 4, 2019, Ohio State News, https://news.osu.edu/depression-affects-one-third-of-lung-cancer-patients/

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Chemical in Wine May Improve Mesothelioma Treatment

    There’s new evidence that a compound found in red wine may help improve the effectiveness of chemotherapy treatment for malignant pleural mesothelioma. Last year, a team of Korean researchers released the world’s first study on the mesothelioma-fighting power of resveratrol, a natural phenol derived from the skin of red grapes and found in red wine and grape juice. Now, the same team says resveratrol also appears to enhance the chemosensitivity of malignant mesothelioma cells. Study author Yoon-Jin Lee and colleagues discovered  a synergistic cancer-fighting effect in mesothelioma cells treated with both resveratrol and clofarabine, a prescription drug often used to treat acute lymphoblastic leukemia. Together, resveratrol and clofarabine “induced a strong cytotoxic effect” by influencing levels of the tumor suppressor,…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…